Abstract:Objective: Analgesic,anti-inflammatory and anti-ulcer were choosed as pharmacological targets to evaluate the pharmacodynamics of Yulian Cataplasm therefore to provide the experimental basis for clinical applications of the cataplasm. Method: The rat experimental gastric ulcer was established by using pyloric ligation. Rat paw edema was caused by inflammation action of carragenan. The mouse model of analgesia was established by the method of somatic wrenching. The effects of Yulian Cataptosm(rats 12,6,3 g ·kg-1, mice 6,3,1.5 g ·kg-1,ig)were evaluated by ulcer index, inhibition rate and the incidence of ulcers, foot swelling, writhing and capillary permeability. Yulian cataplasm of high,middle and low dose groups were used respectively. Result: The external Yulian Cataplasm lowered ulcer index in a dose dependent manner. only the high and middle dose groups could increase excretion of pepsin while reduced the incidence of ulcers. Both middle and low dose groups could reduce rat paw swelling, middle dose group lasted longer duration of action. High and middle dose groups could decrease capillary permeability, all the three dose groups could reduce the writhing, and compared with excipient group, there was significant difference (P<0.05, P<0.01). Conclusion: Yulian Cataplasm could obviously inhibite the gastric ulcer, pain and swelling with the role of anti-inflammatory, it also provided an experimental basis on the feasibility of treating gastrointestinal diseases with transdermal drug delivery.